+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Canadian ENHANCE data support the efficacy and safety of drotrecogin alfa (activated) despite higher disease severity than the global ENHANCE population


      1 , 2 , 3 , 4 , 5 , 2

      Critical Care

      BioMed Central

      25th International Symposium on Intensive Care and Emergency Medicine

      21-25 March 2005

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The ENHANCE trial was an open-label, multi-national (25 countries) study of drotrecogin alfa (activated) (DrotAA) in 2378 patients with severe sepsis (systemic inflammatory response due to acute infection and ≥ 1 sepsis-induced organ dysfunction of ≤ 48 hours duration). In Canada, 305 patients were enrolled at 18 sites. DrotAA was infused for 96 hours at 24 mg/kg/hour. Patients continued to receive supportive care. Table 1 presents baseline characteristics, bleeding events, and 28-day all-cause mortality for Canadian and Global ENHANCE populations. Canadian patients demonstrated higher disease severity at baseline by organ dysfunction and APACHE II, yet had numerically lower mortality and fewer infusion period serious bleeds than the Global ENHANCE overall population. Comparison of laboratory and severity variables between survivors and non-survivors using the Wilcoxon two-sample test suggests that possible predictors of survival in Canadian ENHANCE patients were: first day change in creatinine; number of organ failures at baseline; pre-infusion APACHE II score; and enrollment at PROWESS study sites. In conclusion, differences were observed in disease severity and outcomes in Canadian ENHANCE patients compared with the overall trial sample. Table 1 Baseline characteristics and outcomes Canadian ENHANCE (n = 305) Global ENHANCE (n = 2378) Mean age, years (SD) 56.9 (17.2) 59.1 (16.9) APACHE II ICU (SD) 25.3 (7.8) 22.0 (7.4) # Organ failure (SD) 3.1 (1.2) 2.7 (1.1) Baseline SOFA (SD) 10.9 (3.6) 9.7 (3.5) Vasopressor use (%) 82% 74% Mechanical ventilation (%) 90% 82% Infusion serious bleed (%) 2.0% 3.6% 28-Day serious bleed (%) 3.9% 6.5% Infusion ICH (%) 0.3% 0.6% 28-Day mortality (%) 22.6% 25.3% SD, standard deviation.

          Related collections

          Author and article information

          Crit Care
          Crit Care
          Critical Care
          BioMed Central
          7 March 2005
          : 9
          : Suppl 1
          : P194
          [1 ]Queen Elizabeth II HSC, Halifax, Canada
          [2 ]Eli Lilly Canada Inc., Toronto, Canada
          [3 ]University of Toronto, ON, Canada
          [4 ]University of Ottawa, Canada
          [5 ]St Paul's Hospital, Vancouver, BC, Canada
          Copyright © 2005 BioMed Central Ltd
          25th International Symposium on Intensive Care and Emergency Medicine
          Brussels, Belgium
          21-25 March 2005
          Poster Presentation

          Emergency medicine & Trauma


          Comment on this article